Escitalopram-induced hepatitis: A case report

doi:10.12998/wjcc.v10.i8.2468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11919)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

271

WORD

129

HTML

10193

Tables (1-3)

305

Sum=10898

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

307

Download

714

Sum=1021

Mar 16, 2022 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Mar 16, 2022; 10(8): 2468-2473
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2468

Escitalopram-induced hepatitis: A case report

Guillaume Wabont, Laurie Ferret, Nicolas Houdre, Antoine Lepied, Johana Bene, Etienne Cousein

Guillaume Wabont, Laurie Ferret, Etienne Cousein, Department of Pharmacy, Valenciennes Hospital, Valenciennes 59300, France

Nicolas Houdre, Department of Emergency Medicine, Valenciennes Hospital, Valenciennes 59300, France

Antoine Lepied, Department of Psychiatry, Valenciennes Hospital, Valenciennes 59300, France

Johana Bene, Department of Pharmacology, Lille University Hospital, Lille 59000, France

Author contributions: Wabont G wrote the manuscript; all authors contributed equally to this work and have read and approved the final manuscript.

Informed consent statement: The study participant provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

CARE Checklist (2016) statement: The authors followed the CARE checklist guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Guillaume Wabont, PharmD, Pharmacist, Statistician, Department of Pharmacy, Valenciennes Hospital, Avenue Desandrouin, Valenciennes 59300, France. wabont.guillaume@gmail.com

Received: August 11, 2021
Peer-review started: August 11, 2021
First decision: September 2, 2021
Revised: September 23, 2021
Accepted: February 9, 2022
Article in press: February 9, 2022
Published online: March 16, 2022
Processing time: 211 Days and 10.2 Hours

Core Tip

Core Tip: The antidepressant escitalopram is widely prescribed for the treatment of depression. The article consists of a unique clinical case, a review of the literature and a pharmacovigilance analysis. This is the first clinical case of escitalopram as the only possible drug causing hepatitis and cholestasis. This is also the first pharmacovigilance analysis conducted to qualify and quantify the risk of hepatitis and cholestasis when using escitalopram.